Myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangements (MLN-FGFR1) are rare. Sharing constitutive FGFR1 activation as the driver of uncontrolled cellular proliferation, these malignancies are molecularly diverse, with approximately 20 known rearrangement partners identified to date (ZMYM2 and BCR being the most common).1,2
Oehler et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: